Loading...
Loading...
Vertex
Pharmaceuticals Incorporated
VRTX today announced it has
entered into a non-exclusive agreement with GlaxoSmithKline
GSK to
conduct a Phase 2 proof-of-concept study of an all-oral regimen for the
treatment of hepatitis C containing Vertex's nucleotide analogue
hepatitis C virus (HCV) polymerase inhibitor VX-135 and GSK's NS5A
inhibitor GSK2336805. Vertex and GSK plan to initiate the study in early
2013, pending discussions with regulatory authorities. The study is
expected to evaluate safety, tolerability and viral cure rates using a
12-week combination of VX-135 and GSK2336805. The companies will jointly
fund costs associated with the study. There are no up-front or milestone
payments associated with the agreement. VX-135 is an investigational
uridine nucleotide analogue pro-drug designed
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in